1. Home
  2. ARCT vs IPHA Comparison

ARCT vs IPHA Comparison

Compare ARCT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arcturus Therapeutics Holdings Inc.

ARCT

Arcturus Therapeutics Holdings Inc.

HOLD

Current Price

$5.52

Market Cap

198.1M

Sector

Health Care

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.78

Market Cap

165.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ARCT
IPHA
Founded
2013
1999
Country
United States
France
Employees
N/A
163
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
198.1M
165.3M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
ARCT
IPHA
Price
$5.52
$1.78
Analyst Decision
Buy
Strong Buy
Analyst Count
10
4
Target Price
$24.11
$5.75
AVG Volume (30 Days)
564.0K
6.3K
Earning Date
05-07-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
20.00
N/A
EPS
N/A
N/A
Revenue
$82,031,000.00
N/A
Revenue This Year
N/A
$180.36
Revenue Next Year
$12.77
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.74
$1.18
52 Week High
$24.14
$2.63

Technical Indicators

Market Signals
Indicator
ARCT
IPHA
Relative Strength Index (RSI) 26.97 52.60
Support Level N/A $1.73
Resistance Level $7.98 $1.96
Average True Range (ATR) 0.36 0.05
MACD -0.10 -0.00
Stochastic Oscillator 0.23 39.78

Price Performance

Historical Comparison
ARCT
IPHA

About ARCT Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: